Khan Najat (CIK 2020969) reported 16 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2026-06-05). Recent activity: Sell RXRX (23,588 shares), Sell RXRX (62,701 shares), Sell RXRX (28,298 shares), Sell RXRX (14,280 shares), Buy RXRX (1.7M shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-05 | RECURSION PHARMACEUTICALS, INC. (RXRX) | CEO and President | Sell | 23,588 | $84,459 |
| 2026-05-19 | RECURSION PHARMACEUTICALS, INC. (RXRX) | CEO and President | Sell | 62,701 | $190,611 |
| 2026-03-11 | RECURSION PHARMACEUTICALS, INC. (RXRX) | CEO and President | Sell | 28,298 | $94,798 |
| 2026-02-19 | RECURSION PHARMACEUTICALS, INC. (RXRX) | CEO and President | Sell | 14,280 | $49,837 |
| 2026-02-10 | RECURSION PHARMACEUTICALS, INC. (RXRX) | CEO and President | Buy | 1.7M | $0 |
| 2026-02-10 | RECURSION PHARMACEUTICALS, INC. (RXRX) | CEO and President | Buy | 30,346 | $0 |
| 2026-02-10 | RECURSION PHARMACEUTICALS, INC. (RXRX) | CEO and President | Sell | 10,364 | $41,249 |
| 2025-12-29 | RECURSION PHARMACEUTICALS, INC. (RXRX) | Chief R&D Commercial Officer | Sell | 124,403 | $548,617 |
| 2025-11-19 | RECURSION PHARMACEUTICALS, INC. (RXRX) | Chief R&D Commercial Officer | Sell | 17,584 | $72,798 |
| 2025-11-06 | RECURSION PHARMACEUTICALS, INC. (RXRX) | Chief R&D Commercial Officer | Buy | 84,925 | $0 |
| 2025-08-19 | RECURSION PHARMACEUTICALS, INC. (RXRX) | Chief R&D Commercial Officer | Sell | 3,789 | $21,370 |
| 2025-08-19 | RECURSION PHARMACEUTICALS, INC. (RXRX) | Chief R&D Commercial Officer | Sell | 36,599 | $202,026 |
| 2025-05-19 | RECURSION PHARMACEUTICALS, INC. (RXRX) | Chief R&D Commercial Officer | Sell | 3,796 | $16,133 |
| 2025-02-05 | RECURSION PHARMACEUTICALS, INC. (RXRX) | Chief R&D Commercial Officer | Buy | 210,113 | $0 |
| 2025-02-05 | RECURSION PHARMACEUTICALS, INC. (RXRX) | Chief R&D Commercial Officer | Buy | 8,049 | $0 |
| 2025-02-05 | RECURSION PHARMACEUTICALS, INC. (RXRX) | Chief R&D Commercial Officer | Sell | 2,753 | $19,959 |
Source: SEC Form 4 filings · as of 2026-06-05